本帖最后由 老马 于 2012-1-13 21:20 编辑 2 n8 c& g4 a! c6 i! I, H
. Y) c5 c. z* X% N爱必妥和阿瓦斯丁的比较
+ @# g' b0 P: Y* s+ a
) n/ U# \1 K! M* ?
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ [% a6 w, f2 z* _8 W$ [/ {! M
4 b! q6 I' G# a; `
; j) F$ a z3 K- F4 Y+ Y/ n; c9 Q h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 }3 q9 I- \( Y# m" h
==================================================
; I1 }# x# I- L, y: j0 X2 p( qOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" U3 _# i" a6 y L8 m( M! ~) JPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ R0 T4 Y4 }' [. ^3 x) U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 o' @8 f `2 i8 `/ [
|